source
- Eli Lilly stops disclosing Phase 1 pipeline, making early-stage projects invisible in earnings decksEli Lilly has become more opaque as its size grows, choosing to stop public disclosure of its early-stage research efforts. The shift was noted earlier this year when the company removed Phase 1 pr…
- AstraZeneca explores options after anselamimab fails Phase 3, while Imfinzi and Tremfya receive label expansionsAstraZeneca announced that its experimental monoclonal antibody anselamimab failed to meet the primary endpoint in two Phase 3 trials for a specific patient group. The company said it will explore…